Traws Pharma (NASDAQ:TRAW) Stock Rating Upgraded by LADENBURG THALM/SH SH

Traws Pharma (NASDAQ:TRAW) was upgraded by LADENBURG THALM/SH SH to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

A number of other equities research analysts have also commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a research report on Monday, December 22nd. Wall Street Zen lowered Traws Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. HC Wainwright assumed coverage on Traws Pharma in a report on Wednesday, December 3rd. They set a “buy” rating and a $8.00 target price on the stock. Finally, Zacks Research upgraded Traws Pharma to a “hold” rating in a research note on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Traws Pharma Stock Up 0.5%

Shares of Traws Pharma stock opened at $2.11 on Friday. Traws Pharma has a 12-month low of $0.97 and a 12-month high of $8.61. The stock has a market capitalization of $16.86 million, a P/E ratio of 0.02 and a beta of 1.66. The company has a 50-day simple moving average of $1.91 and a 200 day simple moving average of $1.94.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($9.16) by $8.82. Traws Pharma had a net margin of 3,028.25% and a negative return on equity of 2,883.04%.

Institutional Investors Weigh In On Traws Pharma

A hedge fund recently raised its stake in Traws Pharma stock. Two Sigma Investments LP increased its position in shares of Traws Pharma, Inc. (NASDAQ:TRAW) by 37.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,018 shares of the company’s stock after acquiring an additional 5,955 shares during the quarter. Two Sigma Investments LP owned about 0.31% of Traws Pharma worth $41,000 at the end of the most recent quarter. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.